Logo image of BCTX

BRIACELL THERAPEUTICS CORP (BCTX) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:BCTX - CA1079303071 - Common Stock

8.09 USD
+0.54 (+7.15%)
Last: 12/24/2025, 8:14:52 PM
8.5 USD
+0.41 (+5.07%)
Pre-Market: 12/26/2025, 8:00:04 AM
Fundamental Rating

2

Taking everything into account, BCTX scores 2 out of 10 in our fundamental rating. BCTX was compared to 530 industry peers in the Biotechnology industry. BCTX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. BCTX does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

BCTX had negative earnings in the past year.
BCTX had a negative operating cash flow in the past year.
In the past 5 years BCTX always reported negative net income.
BCTX had a negative operating cash flow in each of the past 5 years.
BCTX Yearly Net Income VS EBIT VS OCF VS FCFBCTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -10M -20M -30M

1.2 Ratios

With a Return On Assets value of -219.56%, BCTX is not doing good in the industry: 90.94% of the companies in the same industry are doing better.
BCTX has a worse Return On Equity (-287.71%) than 73.21% of its industry peers.
Industry RankSector Rank
ROA -219.56%
ROE -287.71%
ROIC N/A
ROA(3y)-91.98%
ROA(5y)-72.56%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BCTX Yearly ROA, ROE, ROICBCTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500 -500 1K -1K 1.5K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for BCTX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BCTX Yearly Profit, Operating, Gross MarginsBCTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025

More info and screens

6

2. Health

2.1 Basic Checks

Compared to 1 year ago, BCTX has more shares outstanding
BCTX has more shares outstanding than it did 5 years ago.
BCTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
BCTX Yearly Shares OutstandingBCTX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500K 1M 1.5M
BCTX Yearly Total Debt VS Total AssetsBCTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M 50M

2.2 Solvency

BCTX has an Altman-Z score of -13.79. This is a bad value and indicates that BCTX is not financially healthy and even has some risk of bankruptcy.
BCTX has a worse Altman-Z score (-13.79) than 78.49% of its industry peers.
BCTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -13.79
ROIC/WACCN/A
WACCN/A
BCTX Yearly LT Debt VS Equity VS FCFBCTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10M -10M 20M -20M

2.3 Liquidity

BCTX has a Current Ratio of 3.42. This indicates that BCTX is financially healthy and has no problem in meeting its short term obligations.
BCTX has a Current ratio of 3.42. This is comparable to the rest of the industry: BCTX outperforms 40.57% of its industry peers.
BCTX has a Quick Ratio of 3.42. This indicates that BCTX is financially healthy and has no problem in meeting its short term obligations.
BCTX's Quick ratio of 3.42 is in line compared to the rest of the industry. BCTX outperforms 42.83% of its industry peers.
Industry RankSector Rank
Current Ratio 3.42
Quick Ratio 3.42
BCTX Yearly Current Assets VS Current LiabilitesBCTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M 50M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for BCTX have decreased strongly by -184.87% in the last year.
EPS 1Y (TTM)-184.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%86.67%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 18.83% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y90.98%
EPS Next 2Y40.47%
EPS Next 3Y25.73%
EPS Next 5Y18.83%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
BCTX Yearly Revenue VS EstimatesBCTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2026 2027 2M 4M 6M 8M 10M
BCTX Yearly EPS VS EstimatesBCTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 -50 -100 -150 -200

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for BCTX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BCTX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BCTX Price Earnings VS Forward Price EarningsBCTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BCTX Per share dataBCTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -20 -40 -60 -80 -100

4.3 Compensation for Growth

A more expensive valuation may be justified as BCTX's earnings are expected to grow with 25.73% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.47%
EPS Next 3Y25.73%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for BCTX!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

BRIACELL THERAPEUTICS CORP

NASDAQ:BCTX (12/24/2025, 8:14:52 PM)

Premarket: 8.5 +0.41 (+5.07%)

8.09

+0.54 (+7.15%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)12-15 2025-12-15
Earnings (Next)03-10 2026-03-10
Inst Owners4.75%
Inst Owner Change-80.12%
Ins Owners0.2%
Ins Owner Change0%
Market Cap15.21M
Revenue(TTM)N/A
Net Income(TTM)-28.71M
Analysts80
Price TargetN/A
Short Float %6.63%
Short Ratio1.85
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)-546.89%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.52
P/tB 1.55
EV/EBITDA N/A
EPS(TTM)-128.19
EYN/A
EPS(NY)-3.43
Fwd EYN/A
FCF(TTM)-15.38
FCFYN/A
OCF(TTM)-15.38
OCFYN/A
SpS0
BVpS5.31
TBVpS5.21
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -219.56%
ROE -287.71%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-91.98%
ROA(5y)-72.56%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.42
Quick Ratio 3.42
Altman-Z -13.79
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-184.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%86.67%
EPS Next Y90.98%
EPS Next 2Y40.47%
EPS Next 3Y25.73%
EPS Next 5Y18.83%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-1.32%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-3.98%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-3.98%
OCF growth 3YN/A
OCF growth 5YN/A

BRIACELL THERAPEUTICS CORP / BCTX FAQ

What is the ChartMill fundamental rating of BRIACELL THERAPEUTICS CORP (BCTX) stock?

ChartMill assigns a fundamental rating of 2 / 10 to BCTX.


What is the valuation status for BCTX stock?

ChartMill assigns a valuation rating of 1 / 10 to BRIACELL THERAPEUTICS CORP (BCTX). This can be considered as Overvalued.


What is the profitability of BCTX stock?

BRIACELL THERAPEUTICS CORP (BCTX) has a profitability rating of 0 / 10.


What is the expected EPS growth for BRIACELL THERAPEUTICS CORP (BCTX) stock?

The Earnings per Share (EPS) of BRIACELL THERAPEUTICS CORP (BCTX) is expected to grow by 90.98% in the next year.